<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03535233</url>
  </required_header>
  <id_info>
    <org_study_id>AA22</org_study_id>
    <nct_id>NCT03535233</nct_id>
  </id_info>
  <brief_title>Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata</brief_title>
  <official_title>Combined Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alopecia areata (AA) presents with circumscribed patches of non-scarring hair loss. It
      inflects a significant psychological and social burden. Many treatment options are used for
      the treatment of AA. Randomized controlled trials comparing intralesional and topical therapy
      and comparing combinations are few.

      The aim of this work is to evaluate the efficacy of combined topical 5% minoxidil and potent
      topical corticosteroid therapy compared to intralesional triamcinolone injection in alopecia
      areata
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical assessment using SALT score (Severity of Alopecia Tool score)</measure>
    <time_frame>3 months</time_frame>
    <description>SALT score is a quantitative assessment scale for the evaluation of percentage of scalp hair loss.
The percent surface area of each of the 4 scalp is determined: Vertex (top): 40% (0.4) of scalp surface area; each side of scalp (right and left profile): each 18% (0.18) of scalp surface area; posterior aspect (back) of scalp: 24% (0.24) of scalp surface area. The percentage of hair loss in any of these 4 aspects is calculated as the percentage of hair loss multiplied by percent surface area of the scalp in that area. SALT score is the sum of product of each section in the above mentioned areas. SALT score is calculated before and after therapy.
Lowest value: 0%: indicates abscence of clinical disease, Highest value: 100%: indicate 100% affection of the scalp</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dermoscopic evaluation</measure>
    <time_frame>3 months</time_frame>
    <description>Dermoscopic assessment of the scalp is performed using DermaLite II Pro HR dermoscope, Germany.
Dermoscopic examination is graded according to a scale provided by Trink and colleagues (2013).
The percentage of dystrophic hairs was evaluated on a 4-point scale as followed:
3= &gt;50% dystrophic hairs
2 = 30-50% dystrophic hairs
1 = 1-29% dystrophic hairs
0 = no dystrophic hairs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative measurement of Transforming growth factor-beta 1 (TGF-β1)</measure>
    <time_frame>3 months</time_frame>
    <description>ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative measurement of Interleukin-23 (IL-23)</measure>
    <time_frame>3 months</time_frame>
    <description>ELISA</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Alopecia Areata</condition>
  <arm_group>
    <arm_group_label>Intralesional group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intralesional triamcinolone acetonide 5 mg/ml monthly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical therapy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Minoxidil 5% topical solution applied twice daily and topical clobetasol propionate 0.05% cream applied once daily every night</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone Acetonide</intervention_name>
    <arm_group_label>Intralesional group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minoxidil 5 % Topical Spray</intervention_name>
    <arm_group_label>Topical therapy group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clobetasol propionate</intervention_name>
    <arm_group_label>Topical therapy group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients presenting with scalp alopecia areata, patchy type, of at least 2 months
             duration.

        Exclusion Criteria:

          -  Alopecia totalis and alopecia universalis.

          -  Alopecia areata solely affecting the beard.

          -  Pregnant and lactating.

          -  Patients known to have autoimmune diseases e.g. autoimmune thyroid disease, vitiligo
             or SLE.

          -  Patients receiving systemic treatment relevant to alopecia areata within 3 months
             before enrollment into the study or topical treatment relevant to alopecia areata
             within 2 months before.

          -  Patients with a dermatological condition affecting the scalp other than AA: e.g.
             psoriasis, eczema.

          -  Patients with psychiatric illness or psychological state interfering with compliance
             or influencing the expectation of the patient.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nermine H El-Eishi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Heba M Mashaly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Solwan I El-Samanoudy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mona MI ElKalioby, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olfat G Shaker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rania M Abdel-Hay, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2018</study_first_submitted>
  <study_first_submitted_qc>May 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2018</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Mona El-Kalioby</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Alopecia areata, intralesional corticosteroid, minoxidil, clobetasol propionate, IL-23, TGFβ-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Clobetasol</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
    <mesh_term>Minoxidil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

